August 25, 2025
| No. | Stock Name | Price(USD) | Bullish | Fair Value(USD) | Financial Health Status | Profitability Rating | Analyst Rating | P/E Ratio | Market Capitalization(USD) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Verizon | 43.45 | +21.55% | 63.00 | Great | Good | Buy | 7.0 | 182.17B |
| 2 | AT&T | 28.15 | +23.38% | 39.00 | Fair | Fair | Neutral | 6.5 | 200.34B |
| 3 | Pfizer | 25.67 | +24.18% | 38.00 | Excellent | Great | Buy | 8.3 | 145.92B |
| 4 | CVS Health | 59.43 | +25.18% | 87.00 | Great | Good | Buy | 10.5 | 79.12B |
| 5 | Intel | 23.01 | +28.65% | 44.90 | Good | Fair | Neutral | 9.2 | 146.80B |
| 6 | Delta Air Lines | 55.19 | +29.85% | 43.50 | Good | Good | Buy | 6.2 | 36.88B |
| 7 | Walgreens | 11.82 | +31.46% | 20.00 | Fair | Poor | Neutral | 7.0 | 18.40B |
| 8 | Citigroup | 96.78 | +32.66% | 102.80 | Good | Fair | Neutral | 6.8 | 179.23B |
| 9 | Ford Motor | 11.45 | +33.93% | 15 | Fair | Fair | Neutral | 5.5 | 44.80B |
| 10 | General Motors | 53.12 | +36.05% | 75 | Good | Good | Buy | 4.5 | 51.34B |
August 25, 2025
| No. | Stock Name | Price(USD) | Bullish | Fair Value(USD) | Financial Health Status | Profitability Rating | Analyst Rating | P/E Ratio | Market Capitalization(USD) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Nike | 72.98 | 65.25% | 77.00 | Strong | Strong | Moderate Buy | 34.8 | 96 B |
| 2 | Procter & Gamble | 155.62 | 145.35% | 178 | Strong | Strong | Buy | 24.7 | 365 B |
| 3 | Intel | 22 | 26.89% | 40 | Healthy | Recovering | Hold / Buy | 14.7 | 140 B |
| 4 | Pfizer | 24.5 | 30.12% | 35 | Ample Cash | Stable | Buy | 12.4 | 157 B |
| 5 | PayPal Holdings | 73.8 | 80.25% | 85 | Capacity | Moderate | Hold | 14.7 | 146 B |
| 6 | Lumen Technologies Inc. | 1.3 | 5.75% | 10 | Strong | Strong | Buy | 10.8 | 167 B |
| 7 | 3M | 159 | 190.45% | 125 | Strong | Recovering | Hold | 10.6 | 55 B |
| 8 | Cisco Systems, Inc. | 46.2 | 50.86% | 65 | Strong | Strong | Moderate Buy | 13.2 | 187 B |
| 9 | CVS Health Corporation | 60 | 62.25% | 70 | Stable | Strong | Moderate Buy | 8.6 | 74 B |
| 10 | Bristol-Myers Squibb | 43.8 | 48.34% | 56 | Strong | Moderate | Buy | 11.6 | 91 B |
